In the last trading session, 1.77 million shares of the Travere Therapeutics Inc (NASDAQ:TVTX) were traded, and its beta was 0.82. Most recently the company’s share price was $15.34, and it changed around -$0.5 or -3.16% from the last close, which brings the market valuation of the company to $1.36B. TVTX currently trades at a discount to its 52-week high of $25.29, offering almost -64.86% off that amount. The share price’s 52-week low was $6.14, which indicates that the current value has risen by an impressive 59.97% since then. We note from Travere Therapeutics Inc’s average daily trading volume that its 10-day average is 2.14 million shares, with the 3-month average coming to 1.80 million.
Travere Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.27. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended TVTX as a Hold, whereas 11 deemed it a Buy, and 0 rated it as Underweight. Travere Therapeutics Inc is expected to report earnings per share of 0.01 for the current quarter.
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Instantly TVTX has showed a red trend with a performance of -3.16% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 17.84 on recent trading dayincreased the stock’s daily price by 14.01%. The company’s shares are currently down -11.94% year-to-date, but still down -9.82% over the last five days. On the other hand, Travere Therapeutics Inc (NASDAQ:TVTX) is -16.31% down in the 30-day period. We can see from the shorts that 10.64 million shares have been sold at a short interest cover period of 5.74 day(s).
The consensus price target as assigned by Wall Street analysts is $21.5, which translates to bulls needing to increase their stock price by 28.65% from its current value. Analyst projections state that TVTX is forecast to be at a low of $12 and a high of $33.
Travere Therapeutics Inc (TVTX) estimates and forecasts
The year-over-year growth rate is expected to be 70.41%, up from the previous year.
Consensus estimates provided by 12 financial analysts predict the company will bring in an average of 101.49M in revenue for the current quarter. 12 analysts expect Travere Therapeutics Inc to make 100.17M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 54.12M and 62.9M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 87.55%. Forecasts for the next quarter put sales growth at 59.26%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -3.34%.
TVTX Dividends
Travere Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Apr-30.
Travere Therapeutics Inc (NASDAQ:TVTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.75% of Travere Therapeutics Inc shares, and 113.16% of them are in the hands of institutional investors. The stock currently has a share float of 114.01%. Travere Therapeutics Inc stock is held by 295.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 9.8642% of the shares, which is about 7.64 million shares worth $62.84 million.
ARMISTICE CAPITAL, LLC, with 9.6774% or 7.5 million shares worth $61.65 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Delaware Group Equity Funds V-Macquarie Small Cap Core Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Feb 28, 2025 . The former held 3.45 shares worth $52.95 million, making up 3.89% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 2.71 shares worth around $41.59 million, which represents about 3.05% of the total shares outstanding.
